GlassScriptPhysician profile
Charles Steven Lancaster
NPI 1316032204
$9,276.78
in general payments reported to CMS, 2019-2025
31 companies · $1,880 in 2025
The $1,880 reported for 2025 was more than what 96% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,351 · 2020: $615 · 2021: $1,549 · 2022: $1,324 · 2023: $836 · 2024: $1,721 · 2025: $1,880.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,355 · Education: $55.00 · Honoraria: $27.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,354.94 |
| Education | $55.00 |
| Honoraria | $27.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,693.63 | 2019-2025 | Rocklatan, Clareon, Tryptyr |
| Bausch & Lomb Americas INC. | $1,107.74 | 2022-2025 | Miebo, Infuse, Xiidra |
| Sun Pharmaceutical Industries INC. | $752.38 | 2019-2025 | Cequa |
| Allergan, INC. | $710.73 | 2019-2022 | |
| Abbvie INC. | $498.06 | 2022-2025 | |
| Johnson & Johnson Vision Care, INC. | $487.98 | 2019-2025 | Acuvue |
| Biotissue Holdings INC. | $480.03 | 2021-2025 | |
| Aerie Pharmaceuticals, INC. | $387.28 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $380.59 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $327.10 | 2019-2021 | |
| Harrow Eye, LLC | $279.54 | 2024-2025 | Vevye, Iheezo |
| Horizon Therapeutics Plc | $251.16 | 2021-2023 | Tepezza |
| Oyster Point Pharma, INC. | $233.24 | 2022-2025 | Tyrvaya |
| Coopervision INC. | $214.66 | 2020-2024 | Clariti Contact Lens |
| Kala Pharmaceuticals, INC. | $209.70 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $150.07 | 2019-2023 | |
| Johnson & Johnson Surgical Vision, INC. | $133.85 | 2021 | |
| Shire North American Group INC | $124.02 | 2019 | |
| Alcon Research LLC | $121.02 | 2019 | |
| Glaukos Corporation | $112.87 | 2022 | |
| Rxsight INC | $104.54 | 2025 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Injector Cartridge |
| Amgen INC. | $96.79 | 2024-2025 | Tepezza |
| Dompe US, INC. | $95.62 | 2022 | |
| Coherus Oncology, INC. | $74.62 | 2022-2023 | |
| Sight Sciences, INC. | $64.67 | 2019-2024 | Omni Surgical System |
| Rayner Intraocular Lenses Limited | $49.90 | 2023-2025 | Omidria, Rayone Aspheric, Rayone Emv |
| Mallinckrodt Hospital Products INC. | $47.72 | 2022 | |
| Ocular Therapeutix, INC. | $41.36 | 2024 | Dextenza |
| Regeneron Healthcare Solutions, INC. | $16.29 | 2020 | |
| Eyepoint US, INC. | $16.23 | 2021 | |
| Eyevance Pharmaceuticals LLC | $13.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Lancaster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.